DSGN - CIK 0001807120
Design Therapeutics, Inc. (DSGN) reported net income of -$69.79M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$69.79M | -40.7% |
| FY 2024 | -$49.59M | +25.8% |
| FY 2023 | -$66.86M | -5.6% |
| FY 2022 | -$63.31M | -78.2% |
| FY 2021 | -$35.53M | -329.1% |
| FY 2020 | -$8.28M | - |
Design Therapeutics, Inc. (DSGN) reported net income of -$69.79M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Design Therapeutics, Inc.'s net income declined from -$8.28M to -$69.79M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.